State of Wyoming Makes New Investment in BioCryst Pharmaceuticals, Inc. $BCRX

State of Wyoming purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 80,638 shares of the biotechnology company’s stock, valued at approximately $672,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE raised its position in BioCryst Pharmaceuticals by 231.6% during the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after acquiring an additional 3,556,208 shares during the period. Pacer Advisors Inc. acquired a new position in shares of BioCryst Pharmaceuticals during the 1st quarter worth approximately $14,880,000. ADAR1 Capital Management LLC acquired a new position in BioCryst Pharmaceuticals during the second quarter worth $1,330,000. Wedge Capital Management L L P NC purchased a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth $3,808,000. Finally, Perceptive Advisors LLC boosted its position in shares of BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after acquiring an additional 4,271,504 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on BCRX. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 24th. JPMorgan Chase & Co. lifted their target price on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 30th. Wedbush lowered their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Finally, Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $13.00 to $11.00 in a report on Thursday, September 10th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $19.44.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $8.47 on Monday. The firm has a 50-day moving average price of $8.63 and a 200 day moving average price of $8.72. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -5.65 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.23 and a 52 week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company’s revenue was up 33.6% on a year-over-year basis. During the same period last year, the company posted $0.15 EPS. Equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.28 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.